No Causal Effect of 25(OH)D on Gestational HTN, Preeclampsia
THURSDAY, June 21, 2018 -- Vitamin D status does not have a causal effect on gestational hypertension or preeclampsia, according to research published online June 20 in The BMJ.
Maria C. Magnus, Ph.D., from the University of Bristol in the United Kingdom, and colleagues used mendelian randomization to examine whether 25-hydroxyvitamin D concentration has a causal effect on gestational hypertension or preeclampsia in two European pregnancy cohorts and two case-control studies. A total of 7,389 women were included in a one-sample mendelian randomization analysis (751 with gestational hypertension and 135 with preeclampsia), while the two-sample mendelian randomization analysis included 3,388 preeclampsia cases and 6,059 controls.
In the conventional multivariable analysis, the researchers found that the relative risk for preeclampsia was 1.03 per 10 percent decrease in 25-hydroxyvitamin D levels and 2.04 for 25-hydroxyvitamin D <25 mmol/L versus ≥75 nmol/L. There was no correlation for gestational hypertension. There was no strong evidence of a linear effect for 25-hydroxyvitamin D on the risk of gestational hypertension or preeclampsia in the one-sample mendelian randomization analysis. In the two-sample mendelian randomization estimate, the odds ratios for preeclampsia were not significant per 10 percent decrease in 25-hydroxyvitamin D level or per unit increase in the log(odds) of 25-hydroxyvitamin D level <75 nmol/L or <50 nmol/L.
"No strong evidence was found to support a causal effect of vitamin D status on gestational hypertension or preeclampsia," the authors write.
One author disclosed financial ties to the biopharmaceutical industry.
© 2020 HealthDay. All rights reserved.
Posted: June 2018
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.